Toronto, ON, Canada, May 12, 2014 -- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Dion Madsen to the Board of Directors. Mr. Madsen is a Senior Managing Partner in the Healthcare Fund at BDC Venture Capital. In this role, he is responsible for overseeing the Healthcare Fund investments and maximizing value creation across the portfolio.
Mr. Madsen brings over 15 years of senior management experience as a financial executive and venture investor, most recently as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures, where he led the completion of the investing cycle for Unilever’s North American Corporate Venture activity. Prior to Unilever, Mr. Madsen led Chiron Corporation’s investor communications, as Director of Investor Relations, and worked in corporate development, building a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history.
“BDC has been an active investor in Interface Biologics since 2004 and the Company continues to be one of our top portfolio companies”, commented Mr. Madsen. “As I’ve started to get more actively involved with the Company, I’m even more impressed with the technology platforms, the commercial success to date and the future prospects. I want to thank Denis Ho for representing BDC on the IBI Board prior to his retirement and his significant contributions. I look forward to working with the management team as a Board member.”
“We are very pleased to have Dion join our Board of Directors", stated Tom Reeves, President and CEO, Interface Biologics. “His deep experience in life sciences venture capital coupled with his understanding of the corporate venture capital and M&A markets will be an invaluable resource for IBI. He’ll be a great addition to our Board. I would also like to thank Denis Ho for his years of support as an IBI Board Member – he has been a big part of our success to date and we will continue to benefit from his guidance and mentorship well into the future."
ABOUT INTERFACE BIOLOGICS, INC.
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic additives and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications